Matthew Galsky

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Matthew Galsky sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).

12 total trials 1 currently recruiting 7 completed early-phase tilt top decile by trial count

Matthew Galsky: 12 sponsored US clinical trials, 1 recruiting.

Matthew Galsky sponsors 12 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 7 completed. 0 of these trials are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Localized Cancer, with 1 trials.

Top-decile sponsor footprint

Matthew Galsky ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 14/100

7 of 10 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (70.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

12 total, page 1 of 1

RECRUITING Phase 2

Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer

NCT06809140
ACTIVE NOT RECRUITING Phase 2

Pembrolizumab in Muscle-invasive Bladder Cancer

NCT05406713
COMPLETED Phase 1

Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer

NCT03359239
COMPLETED Phase 2

Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer

NCT03557918
COMPLETED Phase 2

Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing

NCT03558087
COMPLETED Phase 2

Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer

NCT03451331
COMPLETED Phase 2

Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations

NCT03448718
COMPLETED Phase 2

Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer

NCT02500121
COMPLETED NA

Metformin for Rising PSA Remote Trial

NCT02376166
TERMINATED Phase 1

Phase Ib Study of Gemcitabine Plus Cisplatin or Carboplatin Plus Dovitinib in Patients With Advanced Solid Tumors

NCT01496534
TERMINATED Phase 2

Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma

NCT01331824
TERMINATED Phase 2

First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

NCT01215136

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 9

Therapeutic Areas

Localized Cancer 1
Metastatic Urothelial Cancer 1
Muscle Invasive Bladder Urothelial Carcinoma 1
Muscle-Invasive Bladder Carcinoma 1
Urothelial Carcinoma 1

What is open in the Matthew Galsky pipeline

1 recruiting of 12 indexed (8% open); 7 completed (58%).

Phase mix: 0 late (III/IV) vs 11 early (I/II) (early-phase heavy).

Top condition: Localized Cancer (1 trial), 4 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Matthew Galsky: open-pipeline peers nationwide

Peers matched on 12 registered trials and 8% open enrollment, not the therapeutic-area sidebar.

Matthew Galsky sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 10152025 0%5%10%15%20% Total trials Recruiting share Matthew GalskyAlachua Government ServicesAllergy TherapeuticsAmpio Pharmaceuticals.AngiodynamicsAcrotech BiopharmaAtlanta VA Medical CenterBeacon TherapeuticsBoston VA Research Institute
Matthew Galsky sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Matthew Galsky sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 12 trials (± recruiting share)

Sponsors near 8% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Matthew Galsky page

12 registered trials is a research-attention snapshot, not an endorsement of Matthew Galsky or any single study.

  • 1 of Matthew Galsky's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Localized Cancer is the condition Matthew Galsky studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Localized Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Matthew Galsky pipeline card: 12 registered trials from official public datasets.Report a data error.